Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.73 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.73 |
| ▸ | FABP3 | P05413 | 1/20 | 0.73 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318737 | 0.91 | FABP4 (0.73) | FABP4FABP5FABP3ACHEGRIN1 | |
| SCHEMBL150033 | 0.86 | FABP4 (1.00) | FABP4FABP5FABP3ALDH1A1KDM4E | |
| SCHEMBL30549325 | 0.86 | FABP4 (1.00) | FABP4FABP5FABP3ALDH1A1KDM4E | |
| SCHEMBL1120319 | 0.85 | KDM4E (0.72) | FABP4FABP5FABP3ACHEKDM4E | |
| SCHEMBL17517483 | 0.84 | MAOA (0.67) | FABP4FABP5FABP3ACHEGRIN1 | |
| SCHEMBL27763456 | 0.84 | FABP4 (0.96) | FABP4FABP5FABP3ALDH1A1KDM4E | |
| SCHEMBL13301256 | 0.83 | ACHE (0.52) | FABP4FABP5FABP3ACHEGRIN1 | |
| SCHEMBL1120333 | 0.81 | MAOA (0.59) | FABP4FABP5FABP3ACHEGRIN1 | |
| SCHEMBL17502355 | 0.81 | MAOA (0.78) | FABP4FABP5ACHEGRIN1GRIN2A | |
| SCHEMBL12464615 | 0.81 | MAOA (0.63) | FABP4FABP5FABP3ACHEGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2280968-A2 | PYRIDO [3, 4-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | FABP4 4612/4885FABP5 3298/4885FABP3 4040/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | FABP4 4612/4885FABP5 3298/4885FABP3 4040/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | FABP4 4612/4885FABP5 3298/4885FABP3 4040/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | FABP4 4612/4885FABP5 3298/4885FABP3 4040/4885 |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | FABP4 4667/4885FABP5 3395/4885FABP3 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.